BioNTech SE IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| BioNTech SE | BNTX - NASDAQ |
$18.00-$20.00 | $15.00 | $16.50 | 10 million ADSs | 10/10/2019 |
| JP Morgan, BofA Merrill Lynch, UBS Investment Bank, SVB Leerink | ||||||
Co-Manager(s): Canaccord Genuity, Bryan Garnier & Co., Berenberg, Wolfe Capital Markets, Kempen, Mirae Asset Securities | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-09-09 Terms Added 2019-09-24 Terms Changed 2019-10-09 | ||||||
BioNTech SE Quote & Chart - Click for current quote - BNTX
IPO Boutique aggregates information on public companies and private companies, such as "BNTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About BioNTech SE (adapted from BioNTech SE prospectus):
BioNTech was founded in 2008 on the understanding that every cancer patient's tumor is unique and that in order to effectively address this challenge, we must create individualized treatments for each patient.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
BioNTech was founded in 2008 on the understanding that every cancer patient's tumor is unique and that in order to effectively address this challenge, we must create individualized treatments for each patient.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "BNTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.